KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models

István Kenessey, Krisztina Kói, Orsolya Horváth, Mihály Cserepes, Dávid Molnár, Vera Izsák, Judit Dobos, Balázs Hegedus, József Tóvári, József Tímár

Research output: Contribution to journalArticle

4 Citations (Scopus)


Background: In non-small cell lung cancer (NSCLC) KRAS-mutant status is a negative prognostic and predictive factor. Nitrogen-containing bisphosphonates inhibit prenylation of small G-proteins (e.g. Ras, Rac, Rho) and thus may affect proliferation and migration. In our preclinical work, we investigated the effect of an aminobisphosphonate compound (zoledronic acid) on mutant and wild type KRAS-expressing human NSCLC cell lines. Results: We confirmed that zoledronic acid was unable to inhibit the prenylation of mutant K-Ras unlike in the case of wild type K-Ras. In case of in vitro proliferation, the KRAS-mutant human NSCLC cell lines showed resistance to zoledronic acid wild-type KRAS-cells proved to be sensitive. Combinatory application of zoledronic acid enhanced the cytostatic effect of cisplatin. Zoledronic acid did not induce significant apoptosis. In xenograft model, zoledronic acid significantly reduced the weight of wild type KRAS-EGFR-expressing xenograft tumor by decreasing the proliferative capacity. Futhermore, zoledronic acid induced VEGF expression and improved in vivo tumor vascularization. Materials and methods: Membrane association of K-Ras was examined by Western-blot. In vitro cell viability, apoptotic cell death and migration were measured in NSCLC lines with different molecular background. The in vivo effect of zoledronic acid was investigated in a SCID mouse subcutaneous xenograft model. Conclusions: The in vitro and in vivo inhibitory effect of zoledronic acid was based on the blockade of cell cycle in wild type KRAS-expressing human NSCLC cells. The zoledronic acid induced vascularization supported in vivo cytostatic effect. Our preclinical investigation suggests that patients with wild type KRAS-expressing NSCLC could potentially benefit from aminobisphosphonate therapy.

Original languageEnglish
Pages (from-to)79503-79514
Number of pages12
Issue number48
Publication statusPublished - 2016



  • Human non-small cell lung cancer
  • Ras inhibitor
  • Xenograft model
  • Zoledronic acid

ASJC Scopus subject areas

  • Oncology

Cite this

Kenessey, I., Kói, K., Horváth, O., Cserepes, M., Molnár, D., Izsák, V., Dobos, J., Hegedus, B., Tóvári, J., & Tímár, J. (2016). KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. Oncotarget, 7(48), 79503-79514.